Aarey Drugs & Pharmaceuticals Limited (NSE:AAREYDRUGS) — Stock Price
Aarey Drugs & Pharmaceuticals Limited (NSE:AAREYDRUGS) is currently trading at Rs83.81 INR, up 2.87% today. Over the past 52 weeks, shares have ranged between Rs50.75 and Rs99.25. This page tracks Aarey Drugs & Pharmaceuticals Limited's live share price on the NSE exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see market value of Aarey Drugs & Pharmaceuticals Limited.
Aarey Drugs & Pharmaceuticals Limited (AAREYDRUGS) Stock Price Chart — Daily History & Trading Volume
The chart below tracks Aarey Drugs & Pharmaceuticals Limited's daily closing share price and trading volume on the NSE exchange over the past year, giving a clear view of recent price momentum and liquidity.
Aarey Drugs & Pharmaceuticals Limited Income Statement — Revenue, Profit & Earnings by Year
Aarey Drugs & Pharmaceuticals Limited's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Revenue | Rs4.74 Billion | Rs3.95 Billion | Rs4.19 Billion | Rs4.92 Billion | Rs3.48 Billion |
| Cost of Revenue | Rs4.65 Billion | Rs3.82 Billion | Rs4.04 Billion | Rs4.72 Billion | Rs3.38 Billion |
| Gross Profit | Rs91.32 Million | Rs132.04 Million | Rs115.07 Million | Rs195.45 Million | Rs100.98 Million |
| Research & Development | — | — | — | — | — |
| SG&A | Rs13.38 Million | Rs4.16 Million | Rs8.78 Million | Rs6.14 Million | Rs3.19 Million |
| Total Operating Expenses | Rs88.25 Million | Rs103.80 Million | Rs20.51 Million | Rs100.87 Million | Rs3.96 Million |
| Operating Income | Rs3.06 Million | Rs28.25 Million | Rs135.33 Million | Rs117.74 Million | Rs38.69 Million |
| EBITDA | Rs120.64 Million | Rs114.16 Million | Rs104.50 Million | Rs140.62 Million | Rs116.65 Million |
| EBIT | Rs101.19 Million | Rs97.18 Million | Rs88.77 Million | Rs120.74 Million | Rs107.45 Million |
| Interest Expense | Rs40.17 Million | Rs43.75 Million | Rs28.67 Million | Rs20.37 Million | Rs24.43 Million |
| Income Before Tax | Rs61.02 Million | Rs53.43 Million | Rs60.15 Million | Rs100.27 Million | Rs83.01 Million |
| Income Tax Expense | Rs20.78 Million | Rs6.59 Million | Rs22.39 Million | Rs34.82 Million | Rs17.87 Million |
| Net Income | Rs40.24 Million | Rs46.84 Million | Rs37.71 Million | Rs65.55 Million | Rs65.14 Million |
Aarey Drugs & Pharmaceuticals Limited Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes Aarey Drugs & Pharmaceuticals Limited's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Assets | Rs2.38 Billion | Rs3.03 Billion | Rs2.91 Billion | Rs2.45 Billion | Rs2.33 Billion |
| Total Current Assets | Rs2.13 Billion | Rs2.83 Billion | Rs2.71 Billion | Rs2.19 Billion | Rs2.18 Billion |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | Rs17.56 Million | Rs12.95 Million | Rs4.18 Million | Rs75.07 Million | Rs129.95K |
| Net Receivables | Rs1.60 Billion | Rs1.84 Billion | Rs2.00 Billion | Rs1.36 Billion | Rs1.62 Billion |
| Inventory | Rs454.80 Million | Rs719.94 Million | Rs651.79 Million | Rs561.16 Million | Rs469.27 Million |
| Property, Plant & Equipment | — | — | — | Rs144.67 Million | Rs142.58 Million |
| Goodwill | — | — | — | — | — |
| Total Liabilities | Rs997.86 Million | Rs1.71 Billion | Rs1.74 Billion | Rs1.32 Billion | Rs1.34 Billion |
| Total Current Liabilities | Rs968.80 Million | Rs1.67 Billion | Rs1.68 Billion | Rs1.27 Billion | Rs1.31 Billion |
| Long-term Debt | Rs19.87 Million | Rs32.24 Million | Rs43.61 Million | Rs33.40 Million | Rs0.00 |
| Net Debt | Rs333.83 Million | Rs297.58 Million | Rs370.12 Million | Rs139.71 Million | Rs173.80 Million |
| Total Stockholder Equity | Rs1.38 Billion | Rs1.33 Billion | Rs1.17 Billion | Rs1.14 Billion | Rs988.60 Million |
| Retained Earnings | Rs571.32 Million | Rs531.08 Million | Rs484.25 Million | Rs446.53 Million | Rs381.09 Million |
Aarey Drugs & Pharmaceuticals Limited Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how Aarey Drugs & Pharmaceuticals Limited generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | Rs8.95 Million | Rs-29.94 Million | Rs-12.81 Million | Rs-44.93 Million | Rs54.77 Million |
| Capital Expenditures | Rs52.04 Million | Rs7.22 Million | Rs10.44 Million | Rs22.01 Million | Rs28.79 Million |
| Free Cash Flow | Rs-43.10 Million | Rs-37.16 Million | Rs-23.25 Million | Rs-66.94 Million | Rs25.98 Million |
| Investing Cash Flow | Rs-59.39 Million | Rs-17.02 Million | Rs4.41 Million | Rs-21.97 Million | Rs-28.79 Million |
| Financing Cash Flow | Rs49.24 Million | Rs55.85 Million | Rs13.54 Million | Rs22.53 Million | Rs-24.51 Million |
| Dividends Paid | — | — | — | — | — |
| Stock-Based Compensation | — | — | — | Rs0.00 | Rs0.00 |
| Depreciation | Rs19.45 Million | Rs16.98 Million | Rs15.74 Million | Rs19.88 Million | Rs9.20 Million |
| Change in Cash | Rs-1.21 Million | Rs8.89 Million | Rs5.14 Million | Rs-4.58 Million | Rs1.47 Million |
Aarey Drugs & Pharmaceuticals Limited Earnings History — EPS Actual vs. Analyst Estimates
Track Aarey Drugs & Pharmaceuticals Limited's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| May 28, 2026 | — | — | — |
| Feb 12, 2026 | — | — | — |
| Nov 12, 2025 | — | — | — |
| Aug 12, 2025 | — | — | — |
| Feb 12, 2025 | — | — | — |
| Nov 09, 2024 | — | — | — |